©2024 Stanford Medicine
Fexofenadine Use in Gastroesophageal Reflux Symptoms
Not Recruiting
Trial ID: NCT03425097
Purpose
The investigators wish to study the effectiveness of Fexofenadine (an over the counter
allergy pill) for the treatment of gastroesophageal reflux symptoms in patients who still
have symptoms despite being on a proton pump inhibitor. The investigators will do this by
giving participants both Fexofenadine (an H1 blocker) for 2 weeks and placebo (sugar pill)
for 2 weeks. The participants will not know which drug they are getting at a particular time.
This will help the investigators better assess the true effectiveness of Fexofenadine.
Official Title
A Randomized, Double Blind, Crossover Trial Comparing Fexofenadine to Placebo for the Treatment of Proton Pump Inhibitor Refractory Gastroesophageal Reflux Symptoms
Eligibility
Inclusion Criteria:
- A minimum 6-month history of heartburn and regurgitation, as their main symptom
- Experience at least 3-4 days with episodes of heartburn or regurgitation per week
- Female patients who are postmenopausal or using acceptable methods of birth control.
Exclusion Criteria (selected)
- Esophageal stricture
- Primary esophageal motility disorder
- Systemic sclerosis
- Active inflammatory bowel disease
- Zollinger-Ellison syndrome
- Active gastric or duodenal ulcer
- Active infectious or inflammatory conditions of the small or large intestine
- Malabsorption syndromes of the intestine
- History of gastrointestinal cancer
- Current active cancer
- Prior gastric or intestinal surgery
- Pregnant or breast feeding
- Other serious psychiatric or medical disease
Intervention(s):
drug: Fexofenadine
drug: Placebo - Cap
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
George Triadafilopoulos, MD
(650) 988-7530